Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information
Phone(858) 673-6840
DescriptionTreatment of Liver Disease


San Diego, USA
15010 Avenue of Science
Suite 200
San Diego, CA, 92128


Chief Operating Officer, Executive Vice President
VP, Quality Control & Quality Assurance
VP, Research & Developmen
Vice President, International Operations
Board of Directors
Board of Directors
Board of Directors
Show All People


Convertible Note, 6/2011
Series D, 6/2011
Venture Round, 2/2012
Draper Fisher Jurvetson (DFJ)
Venture Round, 11/2012
Venture Round, 1/2014
Venture Round, 3/2014
Debt, 6/2012


Vital Therapies

Vital Therapies, Inc. is a biotherapeutic company focused on developing a cell-based therapy targeting the treatment of acute liver failure. Our product candidate, the ELAD® System, or ELAD, is a bio-artificial liver therapy that operates outside the body, or extracorporeal, and is designed with the proposed intent to allow the patient’s own liver to regenerate to a healthy state, or to stabilize the patient until liver transplant. ELAD is an allogeneic cellular therapy system incorporating our human liver-derived C3A cells contained in four hollow fiber cartridges that are combined with a single use customized disposable set and a reusable bedside unit. Data from ELAD clinical studies has shown trends that may indicate a potential to increase survival rates in patients with acute liver failure. ELAD has received orphan designation in the United States and Europe for the treatment of acute liver failure. Prior to the initiation of our ongoing Phase III clinical trial program, more than 150 subjects have received ELAD therapy in seven clinical trials and through a compassionate use program, which we believe collectively suggests a promising therapeutic profile. We are currently initiating three Phase III clinical trials in various acute liver failure conditions. In March 2013, we initiated VTI-208, a Phase III randomized, controlled clinical trial in 200 subjects with alcohol-induced liver decompensation. In the fourth quarter of 2013, we intend to initiate two additional Phase III randomized controlled trials, VTI-210, in 120 subjects with acute alcoholic hepatitis, and VTI-212, in 126 subjects with fulminant hepatic failure.

Recent Milestones



Vital Therapies screenshot
Above: Home Page
Uploaded: 3/29/10


  1. SEC ( [edit]
  2. SEC ( [edit]
  3. DFJ report [edit]
  4. SEC ( [edit]
  5. SEC ( [edit]
  6. SEC ( [edit]
  7. SEC D/A ( [edit]
Edit This Page
Last Edited 3/12/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy